CCX-CKR2 Binding Antibodies for Cell Detection and Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of chemokine receptor signaling and selectivity for ligands is limited, particularly for orphan receptors like RDC1, which has not had its endogenous ligand identified, and there is a need for specific antibodies that can bind to CCX-CKR2 to detect and modulate its activity.
Innovation Solution
Development of antibodies comprising specific Kabat complementarity determining regions (CDRs) that bind to CCX-CKR2, allowing for detection of cells expressing CCX-CKR2 and identification of modulators, and testing the efficacy of test agents that modulate CCX-CKR2 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibodies are developed to bind CCX-CKR2, then detection precision and modulation capability are improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent extracts and characterizes specific Kabat complementarity determining regions (CDRs) from antibodies that bind to CCX-CKR2. By identifying and isolating the critical CDR sequences (SEQ ID NO:12, 14, 16, 18) responsible for receptor binding, the invention creates a simplified framework for developing detection and modulation tools without requiring complete antibody characterization or complex structural analysis.
Solution Approach 2:
The patent defines specific amino acid sequences for CDR regions that determine antibody binding specificity to CCX-CKR2. By establishing precise sequence parameters for these complementarity determining regions, the invention enables systematic optimization of antibody variants with different binding affinities and specificities, balancing detection precision with manufacturing feasibility.
2Adaptability or versatility
If specific antibodies binding CCX-CKR2 are developed, then selectivity for ligand detection is improved, but difficulty of detecting and measuring increases
Solution Approach 1:
The patent segments the antibody structure into distinct functional regions, specifically identifying the Kabat CDRs as the critical elements for ligand binding specificity. By focusing on these discrete segments rather than the entire antibody molecule, the invention simplifies the detection and characterization process while maintaining high selectivity for CCX-CKR2 binding.
Solution Approach 2:
The patent replaces complex structural and functional characterization methods with sequence-based identification and analysis of CDR regions. By using amino acid sequence data instead of complex biophysical measurements, the invention makes detection and measurement more accessible while preserving selectivity information.
3Reliability
If antibodies with specific CDR sequences are produced, then binding specificity to CCX-CKR2 is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent establishes specific amino acid sequence parameters for the Kabat CDR regions that determine binding specificity to CCX-CKR2. By defining exact sequence requirements (SEQ ID NO:12, 14, 16, 18), the invention provides clear manufacturing specifications that balance the need for high binding specificity with achievable production precision using standard recombinant antibody technologies.
Data Source
Figure 1
AI summary
Antibodies that bind to CCX-CKR2 and methods of their use are provided.